NCT03684694 is a Phase 1, PHASE2 clinical trial of Loncastuximab Tesirine in Diffuse Large B-Cell Lymphoma, sponsored by ADC Therapeutics S.A..

Who is sponsoring NCT03684694?

NCT03684694 is sponsored by ADC Therapeutics S.A..

What drugs are being tested in NCT03684694?

Interventions in NCT03684694: Loncastuximab Tesirine, Ibrutinib.

What condition does NCT03684694 study?

NCT03684694 studies Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma.

Is NCT03684694 still recruiting?

NCT03684694 is currently terminated. Last updated 6 February 2024.

Are results published for NCT03684694?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-02-06 · How we verify

NCT03684694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Terminated Phase 1, PHASE2 Results posted Last updated 6 February 2024

What this trial tests

Phase 1, PHASE2 trial testing Loncastuximab Tesirine in Diffuse Large B-Cell Lymphoma in 136 participants. Terminated before completion.

Timeline

1 December 2018

Primary endpoint
8 November 2022

8 November 2022

Quick facts

Lead sponsor	ADC Therapeutics S.A.
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	136
Start date	1 December 2018
Primary completion	8 November 2022
Estimated completion	8 November 2022
Sites	35 locations across France, Italy, Belgium, United Kingdom, United States, Spain

Drugs / interventions tested

Loncastuximab Tesirine — full drug profile →
Ibrutinib (ibrutinib) — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →
Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →

Sponsor

ADC Therapeutics S.A. — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Primary · Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)

A TEAE was defined as an adverse event (AE) that occurred or worsened in the period extending from the first dose of study drug to 30 days after the last dose of study drug in this study or start of a new anticancer therapy, whichever is earlier. Any clinically significant changes form baseline in safety laboratory values, vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, and 12-lead electrocardiograms (ECGs) which occurred after first dose of study drug were recorded as TEAEs.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	37
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	4
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	6

Phase 1: Number of Participants With Serious TEAEs Primary · Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)

A serious TEAE was defined as any AE which occurred after the first dose of study drug that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance was not considered a serious adverse event), resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or important medical events that did not meet the preceding criteria but based on appropriate medical judgement may have jeopardized the participant or may have required medic

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	19
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	3

Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) Primary · 21 days

A DLT was defined as any of the following events which occur during the DLT Period (first 21 days of ibrutinib treatment), except those that are clearly due to underlying disease or extraneous causes: a hematologic DLT (grade ≥3 anaemia, grade 4/febrile neutropenia, grade ≥3 thrombocytopenia), a non-hematologic DLT (including aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\] \>3× upper limit of normal (ULN) and bilirubin \>2× ULN), any other non-hematologic toxicities ≥ Grade 3, with exceptions.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	2

Phase 1: Number of Participants With Dose Interruptions Primary · Up to a maximum of 686 days

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	1
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0

Phase 1: Number of Participants With Dose Reductions Primary · Up to a maximum of 686 days

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0

Phase 2: Complete Response Rate (CRR) Primary · Up to approximately 38 months

CRR according to the 2014 Lugano classifications determined by Independent Review Committee (IRC). CRR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR).

Group	Value	95% CI
Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL	27.1	15.3 – 41.8
Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL	26.7	12.3 – 45.9
Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL	90.0	55.5 – 99.7

Phase 1: Overall Response Rate (ORR) Secondary · Up to approximately 38 months

ORR according to the 2014 Lugano classification, defined as the percentage of participants with a BOR of CR or partial response (PR).

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	59.5	42.1 – 75.2
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	50.0	6.8 – 93.2
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	50.0	11.8 – 88.2

Phase 1 and Phase 2: Duration of Response (DOR) Secondary · Up to approximately 36 months

DOR was defined as the time from the first documentation of tumor response to disease progression or death.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	7.49	2.46 – 20.50
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	NA	NA – NA
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	2.50	1.94 – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL	8.25	2.30 – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL	7.64	1.87 – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL	NA	NA – NA

Phase 1 and Phase 2: Relapse-Free Survival (RFS) Secondary · Up to approximately 36 months

RFS was defined as the time from the documentation of CR to disease progression or death.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	7.49	3.61 – 22.28
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	NA	NA – NA
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	1.94	NA – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL	NA	NA – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL	NA	NA – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL	NA	NA – NA

Phase 1 and Phase 2: Progression-Free Survival (PFS) Secondary · Up to approximately 37 months

PFS was defined as the time between start of treatment and the first documentation of progression, or death.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	3.55	1.74 – 7.79
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	3.17	1.22 – NA
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	2.12	0.69 – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL	3.20	1.41 – 4.99
Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL	3.02	1.31 – 6.80
Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL	NA	NA – NA

Phase 1 and Phase 2: Overall Survival (OS) Secondary · Up to approximately 38 months

OS was defined as the time between the start of treatment and death from any cause.

Group	Value	95% CI
Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	14.23	7.82 – 25.99
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	NA	NA – NA
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	NA	NA – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL	8.54	4.57 – 20.60
Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL	16.76	7.16 – NA
Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL	NA	NA – NA

Phase 1 and Phase 2: Time to Reach Maximum Concentration (Tmax) of Loncastuximab Tesirine (Total Antibody, PBD-Conjugated Antibody and Unconjugated Cytotoxin SG3199) Secondary · C1D1 pre-dose, EOI, 4h PD, C1D8 168h PD, C1D15 336h PD, C2D1 pre-dose, EOI, 4h PD, C2D8 168h PD, C2D15 336h PD (3 week cycles)

Blood samples were collected for analysis of PK data of loncastuximab tesirine (total antibody, PBD-conjugated antibody and unconjugated cytotoxin SG3199)

Cycle 1: PBD-conjugated Antibody

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0410	± 122
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0410	± 118
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0330	± 108

Cycle 1: Total Antibody

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0420	± 125
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0410	± 118
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0250	± 21.1

Cycle 1: Unconjugated cytotoxin SG3199

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	14.9	± NA
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	6.94	± NA

Cycle 2: PBD-conjugated Antibody

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0470	± 223
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0.164	± 3347
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0280	± 37.8

Cycle 2: Total Antibody

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0570	± 232
Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0370	± 136
Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0280	± 37.8

Cycle 2: Unconjugated cytotoxin SG3199

Group	Value	95% CI
Phase 1 and Phase 2: 60 µg/kg Loncastuximab Tesirine and Ibrutinib	0.0220	± 19.9

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality reporting was from enrollment until approximately 4 years. For serious adverse events and other adverse events, from Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total), 711 days for Phase 2 (up to approximately 741 days total).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib

Serious: 19/37 (51%)

Deaths: 24/37

Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib

Serious: 0/4 (0%)

Deaths: 0/4

Phase 1: 90 µg/kg Loncastuximab Tesirine and Ibrutinib

Serious: 3/6 (50%)

Deaths: 3/6

Phase 2: Loncastuximab Tesirine and Ibrutinib in Non-Germinal Center B-cell (GCB) DLBCL

Serious: 27/49 (55%)

Deaths: 28/49

Phase 2: Loncastuximab Tesirine and Ibrutinib in GCB DLBCL

Serious: 5/30 (17%)

Deaths: 14/30

Phase 2: Loncastuximab Tesirine and Ibrutinib in MCL

Serious: 5/10 (50%)

Deaths: 3/10

Serious adverse events (66 terms)

Reaction	System	Phase 1: 60 µg/kg Loncastu…	Phase 1: 75 µg/kg Loncastu…	Phase 1: 90 µg/kg Loncastu…	Phase 2: Loncastuximab Tes…	Phase 2: Loncastuximab Tes…	Phase 2: Loncastuximab Tes…
Pneumonia viral	Infections and infestations	—	—	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Death	General disorders	—	—	—	—	—	—
Corona virus infection	Infections and infestations	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Lymph node pain	Blood and lymphatic system disorders	—	—	—	—	—	—
Haemorrhagic disorder	Blood and lymphatic system disorders	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—
Cardiomyopathy	Cardiac disorders	—	—	—	—	—	—
Cardiopulmonary failure	Cardiac disorders	—	—	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—	—	—
Pericardial disease	Cardiac disorders	—	—	—	—	—	—
Pericarditis	Cardiac disorders	—	—	—	—	—	—
Inappropriate antidiuretic hormone secretion	Endocrine disorders	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—

Other adverse events (146 terms — click to expand)

Reaction	System	Phase 1: 60 µg/kg Loncastu…	Phase 1: 75 µg/kg Loncastu…	Phase 1: 90 µg/kg Loncastu…	Phase 2: Loncastuximab Tes…	Phase 2: Loncastuximab Tes…	Phase 2: Loncastuximab Tes…
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Erythema	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—
Weight increased	Investigations	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—
Musculoskeletal pain	Metabolism and nutrition disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Dermatitis bullous	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—

Most-reported serious reactions: Pneumonia viral, General physical health deterioration, Neutropenia, Death, Corona virus infection, Sepsis, Urinary tract infection, Hypercalcaemia.

Data from ClinicalTrials.gov NCT03684694 adverse events section.

Sponsor's own description

The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK. · · 2021 · cited 250× · PMID 33661537 · DOI 10.1002/ajh.26151
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M, Radford J, Carlo-Stella C, Caimi PF, et al · · 2021 · cited 127× · PMID 33211842 · DOI 10.1182/blood.2020007512
New agents and regimens for diffuse large B cell lymphoma.
Wang L, Li LR, Young KH. · · 2020 · cited 109× · PMID 33317571 · DOI 10.1186/s13045-020-01011-z
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
Yu B, Liu D. · · 2019 · cited 70× · PMID 31500657 · DOI 10.1186/s13045-019-0786-6
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
Calabretta E, Hamadani M, Zinzani PL, Caimi P, et al · · 2022 · cited 44× · PMID 35580172 · DOI 10.1182/blood.2021014663
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.
Modi D, Potugari B, Uberti J. · · 2021 · cited 29× · PMID 34830980 · DOI 10.3390/cancers13225827

Verify or expand the search:

Other trials of Loncastuximab Tesirine

Trials testing the same drug.

NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT05672251 — Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting
NCT05453396 — Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · Phase 2 · recruiting
NCT05600686 — Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Ly · Phase 2 · recruiting
NCT05464719 — A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therap · Phase 2 · recruiting

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other ADC Therapeutics S.A. trials

Trials by the same sponsor.

NCT05389462 — A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors · Phase 1 · terminated
NCT05144009 — A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse · Phase 2 · terminated
NCT04970901 — A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer · Phase 1 · recruiting
NCT04974996 — A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Comb · Phase 1 · withdrawn
NCT04699461 — Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or R · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03684694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ADC Therapeutics S.A.
Last refreshed: 6 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing